The Reversal of Drug-Resistance in Tumors Using a Drug-Carrying Nanoparticular System

被引：36

作者：

Oh, Kyung Taek ^{[2
]}

Baik, Hye Jung ^{[1
]}

Lee, A. Hyeong ^{[1
]}

Oh, Young Taik ^{[3
]}

Youn, Yu Seok ^{[4
]}

Lee, Eun Seong ^{[1
]}

机构：

[1] Catholic Univ Korea, Div Biotechnol, Bucheon Si 420743, Gyeonggi Do, South Korea

[2] Chung Ang Univ, Coll Pharm, Seoul 155756, South Korea

[3] Yonsei Univ, Coll Med, Dept Diagnost Radiol, Seoul 120752, South Korea

[4] Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2009年 / 10卷 / 09期

关键词：

multi-drug resistance; nanoparticle; tumor treatment; drug delivery system; MULTIFUNCTIONAL POLYMERIC MICELLE; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; IN-VIVO; LIPOSOMAL DOXORUBICIN; BLOCK-COPOLYMERS; CANCER-THERAPY; CELL-LINES; SOLID TUMORS; EFFLUX PUMP;

D O I：

10.3390/ijms10093776

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Medical applications of nanoparticular systems have attracted considerable attention because of their potential use in therapeutic targeting of disease tissues and their lower level of toxicity against healthy tissue, relative to traditional pharmaceutical drugs. The use of nanoparticular systems has been shown to overcome the limitations of most anticancer drugs in clinical applications. In particular, the improved performance of smarted nanoparticular system for solving the drug resistance problems that typically interrupt tumor treatment has provided a promising strategy for successful tumor chemotherapy. This review highlights recent studies that have examined the therapeutic effect of nanoparticular systems on drug-resistant tumors and presents insight on how they work.

引用

页码：3776 / 3792

页数：17

共 76 条

[1] A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance [J].

Advani, R ;

Lum, BL ;

Fisher, GA ;

Halsey, J ;

Chin, DL ;

Jacobs, CD ;

Sikic, BI .

ANNALS OF ONCOLOGY, 2005, 16 (12) :1968-1973

[2] Fundamental relationships between the composition of Pluronic block copolymers and their hypersensitization effect in MDR cancer cells [J].

Batrakova, E ;

Lee, S ;

Li, S ;

Venne, A ;

Alakhov, V ;

Kabanov, A .

PHARMACEUTICAL RESEARCH, 1999, 16 (09) :1373-1379

[3] Chemoresistance of human malignant melanoma: Cellular and molecular aspects [J].

Berger, W ;

Elbling, L ;

Micksche, M .

ONKOLOGIE, 1998, 21 (02) :105-110

[4] Effects of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymers on structure and stability of liposomal dioleoylphosphatidylethanolamine [J].

Bergstrand, N ;

Edwards, K .

JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2004, 276 (02) :400-407

[5] A family of drug transporters: The multidrug resistance-associated proteins [J].

Borst, P ;

Evers, R ;

Kool, M ;

Wijnholds, J .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1295-1302

[6] A VERSATILE VECTOR FOR GENE AND OLIGONUCLEOTIDE TRANSFER INTO CELLS IN CULTURE AND IN-VIVO - POLYETHYLENIMINE [J].

BOUSSIF, O ;

LEZOUALCH, F ;

ZANTA, MA ;

MERGNY, MD ;

SCHERMAN, D ;

DEMENEIX, B ;

BEHR, JP .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (16) :7297-7301

[7] Cancer chemoresistance: the relationship between p53 and multidrug transporters [J].

Bush, JA ;

Li, G .

INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (03) :323-330

[8]

Chakravarti A, 2002, CANCER RES, V62, P200

[9] An improved method for rapid generation of unmarked Pseudomonas aeruginosa deletion mutants -: art. no. 30 [J].

Choi, KH ;

Schweizer, HP .

BMC MICROBIOLOGY, 2005, 5 (1)

[10] Clinical uses of pegylated pharmaceuticals in oncology [J].

Crawford, J .

CANCER TREATMENT REVIEWS, 2002, 28 :7-11

← 1 2 3 4 5 6 7 8 →